

Cristina Tassorelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7905411/publications.pdf>

Version: 2024-02-01

353
papers

12,869
citations

30070
54
h-index

42399
92
g-index

359
all docs

359
docs citations

359
times ranked

11108
citing authors

#	ARTICLE	IF	CITATIONS
1	Electrokinesiographic Study of Oropharyngeal Swallowing in Neurogenic Dysphagia. <i>Dysphagia</i> , 2023, 38, 543-557.	1.8	5
2	A double-blind randomized controlled trial combining cognitive training (CoRe) and neurostimulation (tDCS) in the early stages of cognitive impairment. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 73-83.	2.9	11
3	From DYMUS to DYPARK: Validation of a Screening Questionnaire for Dysphagia in Parkinson's Disease. <i>Dysphagia</i> , 2022, 37, 824-830.	1.8	4
4	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. <i>Journal of Neurology</i> , 2022, 269, 1335-1352.	3.6	23
5	BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm. <i>Cephalalgia</i> , 2022, 42, 170-175.	3.9	7
6	Validity of the Severity of Dependence Scale for detecting dependence behaviours in chronic migraine with medication overuse. <i>Cephalalgia</i> , 2022, 42, 209-217.	3.9	8
7	Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. <i>Cephalalgia</i> , 2022, 42, 3-11.	3.9	29
8	Headache in 2021: clinical, biological, and genetic advances. <i>Lancet Neurology</i> , The, 2022, 21, 6-8.	10.2	1
9	Tele-healthcare in migraine medicine: from diagnosis to monitoring treatment outcomes. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 237-243.	2.8	8
10	The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. <i>Headache</i> , 2022, 62, 227-240.	3.9	14
11	Facial expressions modulate pain perception in patients with chronic migraine. <i>Cephalalgia</i> , 2022, , 033310242210750.	3.9	1
12	The role of international scientific societies today. <i>Cephalalgia</i> , 2022, , 033310242210920.	3.9	0
13	Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review. <i>Headache</i> , 2022, 62, 453-472.	3.9	9
14	Role of Estrogens in Menstrual Migraine. <i>Cells</i> , 2022, 11, 1355.	4.1	28
15	Non-Invasive Neuromodulation in the Rehabilitation of Pisa Syndrome in Parkinson's Disease: A Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2022, 13, 849820.	2.4	4
16	Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study. <i>Cephalalgia</i> , 2022, , 033310242210937.	3.9	3
17	Machine Learning Approach to Support the Detection of Parkinson's Disease in IMU-Based Gait Analysis. <i>Sensors</i> , 2022, 22, 3700.	3.8	29
18	Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 st edition. <i>Cephalalgia</i> , 2022, 42, 1099-1115.	3.9	5

#	ARTICLE	IF	CITATIONS
19	Pearls & Oy-sters: Marionette walk in Parkinson's disease: a rare dyskinetic-dystonic gait pattern complication improved by visual cueing. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200714.	1.1	2
20	Migraine-attributed burden, impact and disability, and migraine-impacted quality of life: Expert consensus on definitions from a Delphi process. <i>Cephalalgia</i> , 2022, 42, 1387-1396.	3.9	7
21	Potential of endocannabinoids and other lipid amides prevents hyperalgesia and inflammation in a pre-clinical model of migraine. <i>Journal of Headache and Pain</i> , 2022, 23, .	6.0	3
22	Characterization of CB2 Receptor Expression in Peripheral Blood Monocytes of Acute Ischemic Stroke Patients. <i>Translational Stroke Research</i> , 2021, 12, 550-558.	4.2	13
23	A double-blind randomized controlled trial of the efficacy of cognitive training delivered using two different methods in mild cognitive impairment in Parkinson's disease: preliminary report of benefits associated with the use of a computerized tool. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 1567-1575.	2.9	18
24	Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study. <i>Cephalalgia</i> , 2021, 41, 185-196.	3.9	18
25	Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine. <i>Neurotherapeutics</i> , 2021, 18, 556-568.	4.4	8
26	Anodal transcranial direct current stimulation in chronic migraine and medication overuse headache: A pilot double-blind randomized sham-controlled trial. <i>Clinical Neurophysiology</i> , 2021, 132, 126-136.	1.5	23
27	Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine. <i>Neurobiology of Disease</i> , 2021, 147, 105157.	4.4	29
28	Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). <i>Quality of Life Research</i> , 2021, 30, 105-115.	3.1	14
29	Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study. <i>Cephalalgia</i> , 2021, 41, 197-202.	3.9	6
30	Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. <i>Cephalalgia</i> , 2021, 41, 279-293.	3.9	24
31	Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells. <i>Movement Disorders</i> , 2021, 36, 1267-1272.	3.9	22
32	Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks. <i>Pain</i> , 2021, 162, 2376-2385.	4.2	8
33	Clinical and Electrophysiological Outcome Measures of Patients With Post-Infectious Neurological Syndromes Related to COVID-19 Treated With Intensive Neurorehabilitation. <i>Frontiers in Neurology</i> , 2021, 12, 643713.	2.4	9
34	Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization. <i>Pain and Therapy</i> , 2021, 10, 287-314.	3.2	37
35	Telemedicine and Virtual Reality at Time of COVID-19 Pandemic: An Overview for Future Perspectives in Neurorehabilitation. <i>Frontiers in Neurology</i> , 2021, 12, 646902.	2.4	39
36	Isolated bulbar palsy after SARS-CoV-2 infection. <i>Lancet Neurology</i> , The, 2021, 20, 169-170.	10.2	10

#	ARTICLE	IF	CITATIONS
37	The Smart Aging Platform for Assessing Early Phases of Cognitive Impairment in Patients With Neurodegenerative Diseases. <i>Frontiers in Psychology</i> , 2021, 12, 635410.	2.1	14
38	Migraine: integrated approaches to clinical management and emerging treatments. <i>Lancet</i> , The, 2021, 397, 1505-1518.	13.7	139
39	Electrical Stimulation of Injected Muscles to Boost Botulinum Toxin Effect on Spasticity: Rationale, Systematic Review and State of the Art. <i>Toxins</i> , 2021, 13, 303.	3.4	5
40	Lasmiditan: an additional therapeutic option for the acute treatment of migraine. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 491-502.	2.8	6
41	Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. <i>Cephalalgia</i> , 2021, 41, 1135-1151.	3.9	19
42	Evaluation of the efficacy of physical therapy on cognitive decline at 6-month follow-up in Parkinson disease patients with mild cognitive impairment: a randomized controlled trial. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 3275-3284.	2.9	8
43	Ability of a Set of Trunk Inertial Indexes of Gait to Identify Gait Instability and Recurrent Fallers in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 3449.	3.8	13
44	CD163 as a Potential Biomarker of Monocyte Activation in Ischemic Stroke Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6712.	4.1	11
45	High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients. <i>Cephalalgia</i> , 2021, 41, 1437-1446.	3.9	15
46	Gene polymorphism association studies in cluster headache: A field synopsis and systematic meta-analysis. <i>Headache</i> , 2021, 61, 1060-1076.	3.9	7
47	Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. MyE-LIFE European Delphi survey. <i>European Journal of Pain</i> , 2021, 25, 2177-2189.	2.8	1
48	The contribution of the Italian residents in neurology to the COVID-19 crisis: admirable generosity but neurological training remains their priority. <i>Neurological Sciences</i> , 2021, 42, 4425-4431.	1.9	1
49	Neuropathological findings from COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: A critical systematic review. <i>European Journal of Neurology</i> , 2021, 28, 3856-3865.	3.3	64
50	Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine. <i>Cells</i> , 2021, 10, 2543.	4.1	19
51	Consensus on the treatment of dysphagia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021, 430, 120008.	0.6	23
52	The Effects of Intensive Neurorehabilitation on Sequence Effect in Parkinson's Disease Patients With and Without Freezing of Gait. <i>Frontiers in Neurology</i> , 2021, 12, 723468.	2.4	2
53	PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine. <i>Pain Management</i> , 2021, 11, 647-654.	1.5	12
54	Thalamocortical Connectivity in Experimentally-Induced Migraine Attacks: A Pilot Study. <i>Brain Sciences</i> , 2021, 11, 165.	2.3	13

#	ARTICLE	IF	CITATIONS
55	Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. <i>Journal of Headache and Pain</i> , 2021, 22, 114.	6.0	31
56	Expression of Selected microRNAs in Migraine: A New Class of Possible Biomarkers of Disease?. <i>Processes</i> , 2021, 9, 2199.	2.8	6
57	HomeCoRe for Telerehabilitation in Mild or Major Neurocognitive Disorders: A Study Protocol for a Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2021, 12, 752830.	2.4	8
58	Animals Models for Trigeminal Autonomic Cephalalgias. <i>Headache</i> , 2020, , 103-115.	0.4	1
59	Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. <i>European Journal of Neurology</i> , 2020, 27, 536-541.	3.3	47
60	FAAH inhibition as a preventive treatment for migraine: A pre-clinical study. <i>Neurobiology of Disease</i> , 2020, 134, 104624.	4.4	33
61	Experimentally induced spinal nociceptive sensitization increases with migraine frequency: a single-blind controlled study. <i>Pain</i> , 2020, 161, 429-438.	4.2	11
62	Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?. <i>Journal of Headache and Pain</i> , 2020, 21, 122.	6.0	28
63	What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1275-1286.	2.8	14
64	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. <i>Cephalalgia</i> , 2020, 40, 1026-1044.	3.9	105
65	Non-invasive vagus nerve stimulation for primary headache: A clinical update. <i>Cephalalgia</i> , 2020, 40, 1370-1384.	3.9	26
66	Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study. <i>Cephalalgia</i> , 2020, 40, 1336-1345.	3.9	14
67	Intranasal midazolam for treating acute respiratory crises in a woman with stiff person syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	4
68	Migraine neuroscience: from experimental models to target therapy. <i>Neurological Sciences</i> , 2020, 41, 351-361.	1.9	7
69	Non-invasive Brain and Spinal Stimulation for Pain and Related Symptoms in Multiple Sclerosis: A Systematic Review. <i>Frontiers in Neuroscience</i> , 2020, 14, 547069.	2.8	12
70	European Academy of Neurology guideline on the management of medicationâ€overuse headache. <i>European Journal of Neurology</i> , 2020, 27, 1102-1116.	3.3	69
71	Reproducibility and reaction time of swallowing as markers of dysphagia in parkinsonian syndromes. <i>Clinical Neurophysiology</i> , 2020, 131, 2200-2208.	1.5	4
72	Cerebellar ataxia, neuropathy, vestibular areflexia syndrome due to RFC1 repeat expansion. <i>Brain</i> , 2020, 143, 480-490.	7.6	140

#	ARTICLE	IF	CITATIONS
73	Have the IHS <i>Guidelines for controlled trials of acute treatment of migraine attacks</i> been followed? Laying the ground for the 4th edition. Cephalalgia, 2020, 40, 778-787.	3.9	4
74	Anodal transcranial direct current stimulation and intermittent thetaâ€burst stimulation improve deglutition and swallowing reproducibility in elderly patients with dysphagia. Neurogastroenterology and Motility, 2020, 32, e13791.	3.0	18
75	Chronic migraine and Botulinum Toxin Type A: Where do paths cross?. Toxicon, 2020, 178, 69-76.	1.6	12
76	COVIDâ€19: what if the brain had a role in causing the deaths?. European Journal of Neurology, 2020, 27, e41-e42.	3.3	46
77	Cognitive Telerehabilitation for Older Adults With Neurodegenerative Diseases in the COVID-19 Era: A Perspective Study. Frontiers in Neurology, 2020, 11, 623933.	2.4	41
78	Headache and the Heart. , 2020, , 517-527.		0
79	Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the COMOESTAS Project. Cephalalgia, 2019, 39, 135-147.	3.9	25
80	Economic benefits of treating medication-overuse headache â€ results from the multicenter COMOESTAS project. Cephalalgia, 2019, 39, 274-285.	3.9	29
81	Noninvasive peripheral vagal nerve stimulation prevents migraine aura: A case report. Cephalalgia Reports, 2019, 2, 251581631985560.	0.7	1
82	Personality and Personality Disorders in Medication-Overuse Headache: A Controlled Study by SWAP-200. Pain Research and Management, 2019, 2019, 1-9.	1.8	15
83	Hormonally Related Headaches. ISGE Series, 2019, , 93-100.	0.2	0
84	A computer-based cognitive training in Mild Cognitive Impairment in Parkinsonâ€™s Disease. NeuroRehabilitation, 2019, 44, 555-567.	1.3	24
85	Proprioceptive Focal Stimulation (EquistasiÂ®) May Improve the Quality of Gait in Middle-Moderate Parkinson's Disease Patients. Double-Blind, Double-Dummy, Randomized, Crossover, Italian Multicentric Study. Frontiers in Neurology, 2019, 10, 998.	2.4	25
86	Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Doubleâ€Blind Placeboâ€Controlled Phase 3 Clinical Studies. Headache, 2019, 59, 1788-1801.	3.9	31
87	Clinical Subtypes of Medication Overuse Headache â€ Findings From a Large Cohort. Headache, 2019, 59, 1481-1491.	3.9	15
88	Immersive Virtual Reality and Virtual Embodiment for Pain Relief. Frontiers in Human Neuroscience, 2019, 13, 279.	2.0	125
89	OnabotulinumtoxinA Reduces Temporal Pain Processing at Spinal Level in Patients with Lower Limb Spasticity. Toxins, 2019, 11, 359.	3.4	9
90	A pilot study on the efficacy of transcranial direct current stimulation applied to the pharyngeal motor cortex for dysphagia associated with brainstem involvement in multiple sclerosis. Clinical Neurophysiology, 2019, 130, 1017-1024.	1.5	17

#	ARTICLE	IF	CITATIONS
91	Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia, 2019, 39, 1058-1066.	3.9	4
92	Negative Short-Term Outcome of Detoxification Therapy in Chronic Migraine With Medication Overuse Headache: Role for Early Life Traumatic Experiences and Recent Stressful Events. Frontiers in Neurology, 2019, 10, 173.	2.4	16
93	The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment. Frontiers in Human Neuroscience, 2019, 13, 31.	2.0	24
94	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine in children and adolescents, 1st edition. Cephalalgia, 2019, 39, 803-816.	3.9	36
95	Nitroglycerin as a comparative experimental model of migraine pain: From animal to human and back. Progress in Neurobiology, 2019, 177, 15-32.	5.7	76
96	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia, 2019, 39, 687-710.	3.9	154
97	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. Journal of Headache and Pain, 2019, 20, 15.	6.0	7
98	Azithromycin Affords Neuroprotection in Rat Undergone Transient Focal Cerebral Ischemia. Frontiers in Neuroscience, 2019, 13, 1256.	2.8	15
99	Gender Differences in the Clinical Presentation of Cluster Headache: A Role for Sexual Hormones?. Frontiers in Neurology, 2019, 10, 1220.	2.4	27
100	The endocannabinoid system in migraine: from bench to pharmacy and back. Current Opinion in Neurology, 2019, 32, 405-412.	3.6	19
101	Dissecting out migraine complexity through comprehensive analysis of allodynia. Brain, 2019, 142, 5-8.	7.6	2
102	Getting closer to a cure for migraine. Nature Reviews Neurology, 2019, 15, 64-65.	10.1	6
103	Using a Genetic Risk Score Approach to Predict Headache Response to Triptans in Migraine Without Aura. Journal of Clinical Pharmacology, 2019, 59, 288-294.	2.0	10
104	Headache and the Heart. , 2019, , 1-11.		0
105	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia, 2018, 38, 815-832.	3.9	245
106	Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action. Neurotherapeutics, 2018, 15, 313-323.	4.4	73
107	Factors associated to chronic migraine with medication overuse: A cross-sectional study. Cephalalgia, 2018, 38, 2045-2057.	3.9	27
108	Cues and Body-Weight-Supported (BWS) Gait Training in Parkinson's Disease. Biosystems and Biorobotics, 2018, , 357-366.	0.3	2

#	ARTICLE	IF	CITATIONS
109	The Treatment of Axial and Foot Dystonia. Biosystems and Biorobotics, 2018, , 171-185.	0.3	0
110	Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics, 2018, 18, 167-176.	2.8	24
111	The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. Journal of Headache and Pain, 2018, 19, 15.	6.0	23
112	Pain in focal dystonias “ A focused review to address an important component of the disease. Parkinsonism and Related Disorders, 2018, 54, 17-24.	2.2	38
113	When cervical pain is actually migraine: An observational study in 207 patients. Cephalalgia, 2018, 38, 383-388.	3.9	28
114	Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project. Cephalalgia, 2018, 38, 646-654.	3.9	18
115	Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemia-reperfusion injury. Journal of Neuroscience Research, 2018, 96, 151-159.	2.9	23
116	A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache. Cephalalgia, 2018, 38, 1361-1373.	3.9	28
117	Botulinum toxin for chronic migraine: Clinical trials and technical aspects. Toxicon, 2018, 147, 111-115.	1.6	9
118	Peripheral vagal nerve stimulation modulates the nociceptive withdrawal reflex in healthy subjects: A randomized, cross-over, sham-controlled study. Cephalalgia, 2018, 38, 1658-1664.	3.9	19
119	Inhibition of monoacylglycerol lipase: Another signalling pathway for potential therapeutic targets in migraine?. Cephalalgia, 2018, 38, 1138-1147.	3.9	12
120	Effect of Non-invasive Vagus Nerve Stimulation on Resting-State Electroencephalography and Laser-Evoked Potentials in Migraine Patients: Mechanistic Insights. Frontiers in Human Neuroscience, 2018, 12, 366.	2.0	14
121	Antagonism of Transient Receptor Potential Ankyrin Type-1 Channels as a Potential Target for the Treatment of Trigeminal Neuropathic Pain: Study in an Animal Model. International Journal of Molecular Sciences, 2018, 19, 3320.	4.1	32
122	Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 101.	6.0	34
123	Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 98.	6.0	18
124	Prolonged migraine aura: new insights from a prospective diary-aided study. Journal of Headache and Pain, 2018, 19, 77.	6.0	20
125	Traumatic Experiences, Stressful Events, and Alexithymia in Chronic Migraine With Medication Overuse. Frontiers in Psychology, 2018, 9, 704.	2.1	30
126	Endocannabinoid System and Migraine Pain: An Update. Frontiers in Neuroscience, 2018, 12, 172.	2.8	48

#	ARTICLE	IF	CITATIONS
127	Chronic and intermittent administration of systemic nitroglycerin in the rat induces an increase in the gene expression of CGRP in central areas: potential contribution to pain processing. <i>Journal of Headache and Pain</i> , 2018, 19, 51.	6.0	42
128	Botulinum toxin A modifies nociceptive withdrawal reflex in subacute stroke patients. <i>Brain and Behavior</i> , 2018, 8, e01069.	2.2	10
129	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. <i>Lancet Neurology</i> , The, 2018, 17, 597-608.	10.2	101
130	Noninvasive vagus nerve stimulation as acute therapy for migraine. <i>Neurology</i> , 2018, 91, e364-e373.	1.1	186
131	Body Weight Support Combined With Treadmill in the Rehabilitation of Parkinsonian Gait: A Review of Literature and New Data From a Controlled Study. <i>Frontiers in Neurology</i> , 2018, 9, 1066.	2.4	16
132	Alexithymia in chronic and episodic migraine: a comparative study. <i>Journal of Mental Health</i> , 2017, 26, 192-196.	1.9	26
133	Falls, fractures and bone density in Parkinson's disease— a cross-sectional study. <i>International Journal of Neuroscience</i> , 2017, 127, 299-304.	1.6	10
134	Polarization of Microglia/Macrophages in Brain Ischaemia: Relevance for Stroke Therapy. <i>Springer Series in Translational Stroke Research</i> , 2017, , 303-328.	0.1	0
135	Mutations in TMEM230 are not a common cause of Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 302-304.	3.9	14
136	Modulation of cerebral RAGE expression following nitric oxide synthase inhibition in rats subjected to focal cerebral ischemia. <i>European Journal of Pharmacology</i> , 2017, 800, 16-22.	3.5	11
137	Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. <i>Journal of Headache and Pain</i> , 2017, 18, 38.	6.0	37
138	Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms. <i>Cephalalgia</i> , 2017, 37, 1272-1284.	3.9	39
139	Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study. <i>Clinical Neurophysiology</i> , 2017, 128, 1978-1984.	1.5	10
140	Board Walk – April 2017. <i>Cephalalgia</i> , 2017, 37, 401-402.	3.9	0
141	Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. <i>Journal of Headache and Pain</i> , 2017, 18, 66.	6.0	27
142	Clinical features of migraine aura: Results from a prospective diary-aided study. <i>Cephalalgia</i> , 2017, 37, 979-989.	3.9	105
143	The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. <i>Cephalalgia</i> , 2017, 37, 1115-1125.	3.9	48
144	Botulinum Toxin Is Effective in the Management of Neurogenic Dysphagia. Clinical-Electrophysiological Findings and Tips on Safety in Different Neurological Disorders. <i>Frontiers in Pharmacology</i> , 2017, 8, 80.	3.5	36

#	ARTICLE	IF	CITATIONS
145	Smart Aging Platform for Evaluating Cognitive Functions in Aging: A Comparison with the MoCA in a Normal Population. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 379.	3.4	27
146	The Grand Challenge in Cranial Pain—From Migraine to Cranial Neuralgias: Understanding Differences and Similarities to Advance Knowledge and Management. <i>Frontiers in Neurology</i> , 2017, 8, 19.	2.4	0
147	Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism Impacts on Migraine Susceptibility: A Meta-analysis of Case–Control Studies. <i>Frontiers in Neurology</i> , 2017, 8, 159.	2.4	15
148	The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model. <i>Journal of Headache and Pain</i> , 2017, 18, 94.	6.0	50
149	Assessing and treating primary headaches and cranio-facial pain in patients undergoing rehabilitation for neurological diseases. <i>Journal of Headache and Pain</i> , 2017, 18, 99.	6.0	22
150	Nonparalytic botulinum molecules for the control of pain. <i>Pain</i> , 2016, 157, 1045-1055.	4.2	33
151	Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study. <i>Journal of Headache and Pain</i> , 2016, 17, 70.	6.0	19
152	Specific patterns of laryngeal electromyography during wakefulness are associated to sleep disordered breathing and nocturnal stridor in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 104-109.	2.2	14
153	Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. <i>Journal of Headache and Pain</i> , 2016, 17, 20.	6.0	34
154	Headache, depression and anxiety: associations in the Eurolight project. <i>Journal of Headache and Pain</i> , 2016, 17, 59.	6.0	145
155	Interictal burden attributable to episodic headache: findings from the Eurolight project. <i>Journal of Headache and Pain</i> , 2016, 17, 9.	6.0	92
156	Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype. <i>Experimental Neurology</i> , 2016, 275, 116-125.	4.1	81
157	Psychological factors associated with failure of detoxification treatment in chronic headache associated with medication overuse. <i>Cephalalgia</i> , 2016, 36, 1356-1365.	3.9	28
158	Variability of the characteristics of a migraine attack within patients. <i>Cephalalgia</i> , 2016, 36, 825-830.	3.9	41
159	Migraine aura symptoms: Duration, succession and temporal relationship to headache. <i>Cephalalgia</i> , 2016, 36, 413-421.	3.9	48
160	Andrographis Paniculata shows anti-nociceptive effects in an animal model of sensory hypersensitivity associated with migraine. <i>Functional Neurology</i> , 2016, 31, 53-60.	1.3	9
161	Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectiology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. <i>European Journal of Physical and Rehabilitation Medicine</i> . 2016, 52, 841-854.	2.2	14
162	Headache, low back pain, other nociceptive and mixed pain conditions in neurorehabilitation. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2016, 52, 867-880.	2.2	10

#	ARTICLE	IF	CITATIONS
163	P043. Hyperechogenicity of the periaqueductal gray in chronic migraine and episodic migraine as a potential marker of progressive dysfunction: preliminary results with transcranial sonography. Journal of Headache and Pain, 2015, 16, A61.	6.0	4
164	O029. Lessons from the expert patients. Advice for the physician to improve the care of cluster headache patients. Journal of Headache and Pain, 2015, 16, A94.	6.0	1
165	O010. Migraine aura symptoms last for more than one hour in more than one quarter of patients: results from a prospective diary-aided study. Journal of Headache and Pain, 2015, 16, A65.	6.0	1
166	O001. The Italian Consensus Conference "Chronic Pain in Neurorehabilitation" Group 29: headache and facial pain. Journal of Headache and Pain, 2015, 16, A132.	6.0	0
167	Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy. Journal of Headache and Pain, 2015, 16, 532.	6.0	32
168	Association of <i>RAMP1</i> With the Risk of Migraine Transformation Into Medication Overuse Headache. Headache, 2015, 55, 658-668.	3.9	18
169	P008. Alexithymia and chronic migraine with medication overuse: what relationship?. Journal of Headache and Pain, 2015, 16, A150.	6.0	4
170	P007. Inhibition of monoacylglycerol lipase activity modulates the activation of brain structures relevant for migraine pathogenesis. Journal of Headache and Pain, 2015, 16, A165.	6.0	0
171	Rehabilitation from symptomatic drugs overuse: yes, no, may be. Journal of Headache and Pain, 2015, 16, A34.	6.0	0
172	O011. Patients with "prolonged aura" do not show clinical or demographic differences from the patients with "typical aura". Journal of Headache and Pain, 2015, 16, A67.	6.0	2
173	O012. Intra-variability of the characteristics of migraine attacks. Journal of Headache and Pain, 2015, 16, A70.	6.0	1
174	Clinical and Demographical Characteristics of Patients with Medication Overuse Headache in Argentina and Chile: Analysis of the Latin American Section of COMOESTAS Project. Journal of Headache and Pain, 2015, 16, 83.	6.0	30
175	Impact of headache disorders in Italy and the public-health and policy implications: a population-based study within the Eurolight Project. Journal of Headache and Pain, 2015, 16, 100.	6.0	48
176	Acute and Chronic Effect of Acoustic and Visual Cues on Gait Training in Parkinson's Disease: A Randomized, Controlled Study. Parkinson's Disease, 2015, 2015, 1-9.	1.1	17
177	Acute effects of high-frequency microfocal Cortical excitability changes over time in progressive multiple sclerosis muscle. A double-blind study in healthy subjects. Functional Neurology, 2015, 30, 269-74.	1.3	10
178	Animal Models of Tension-Type Headache and Trigeminal Autonomic Cephalalgias. Headache, 2015, , 67-82.	0.4	0
179	Rational modulation of the innate immune system for neuroprotection in ischemic stroke. Frontiers in Neuroscience, 2015, 9, 147.	2.8	168
180	Evaluation of ADMA-DDAH-NOS axis in specific brain areas following nitroglycerin administration: study in an animal model of migraine. Journal of Headache and Pain, 2015, 16, 560.	6.0	31

#	ARTICLE	IF	CITATIONS
181	Triptan use in Italy: Insights from administrative databases. <i>Cephalalgia</i> , 2015, 35, 619-626.	3.9	19
182	Endocannabinoids and migraine. , 2015, , 173-189.		1
183	Effects of peripheral FAAH blockade on NTC-induced hyperalgesia—evaluation of URB937 in an animal model of migraine. <i>Cephalalgia</i> , 2015, 35, 1065-1076.	3.9	50
184	Spinal Autophagy is Differently Modulated in Distinct Mouse Models of Neuropathic Pain. <i>Molecular Pain</i> , 2015, 11, 1744-8069-11-3.	2.1	54
185	Role of D-Limonene in Autophagy Induced by Bergamot Essential Oil in SH-SY5Y Neuroblastoma Cells. <i>PLoS ONE</i> , 2014, 9, e113682.	2.5	44
186	Early reperfusion injury is associated to MMP2 and IL-1 β elevation in cortical neurons of rats subjected to middle cerebral artery occlusion. <i>Neuroscience</i> , 2014, 277, 755-763.	2.3	27
187	Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1195-1202.	1.9	18
188	EHMTI-0045. The succession of aura and headache: a prospective diary-based study. <i>Journal of Headache and Pain</i> , 2014, 15, .	6.0	0
189	EHMTI-0141. URB937 as a potential therapeutic option for migraine: evaluation in animal model of migraine. <i>Journal of Headache and Pain</i> , 2014, 15, .	6.0	0
190	EHMTI-0111. Intra-variability of migraine attacks features. <i>Journal of Headache and Pain</i> , 2014, 15, .	6.0	1
191	Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. <i>European Journal of Pharmacology</i> , 2014, 744, 91-97.	3.5	19
192	Pharmacogenomics of episodic migraine: time has come for a step forward. <i>Pharmacogenomics</i> , 2014, 15, 541-549.	1.3	11
193	Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). <i>Cephalalgia</i> , 2014, 34, 426-433.	3.9	106
194	EHMTI-0043. Clinically-oriented stratified approach and patient-preference approach in the management of MOH — a comparison between two strategies. <i>Journal of Headache and Pain</i> , 2014, 15, .	6.0	0
195	EHMTI-0147. Medication overuse headache and alexithymia: a controlled study. <i>Journal of Headache and Pain</i> , 2014, 15, .	6.0	0
196	EHMTI-0305. Psychological assessment of patients with chronic refractory headache: a consecutive case series. <i>Journal of Headache and Pain</i> , 2014, 15, .	6.0	0
197	EHMTI-0035. "Cervical pain" study in an Italian tertiary referral headache center. <i>Journal of Headache and Pain</i> , 2014, 15, .	6.0	0
198	EHMTI-0024. The typical duration of migraine aura: a prospective diary-based study. <i>Journal of Headache and Pain</i> , 2014, 15, .	6.0	0

#	ARTICLE	IF	CITATIONS
199	Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. <i>Journal of Headache and Pain</i> , 2014, 15, 14.	6.0	30
200	EHMTI-0046. The succession of aura symptoms: a prospective diary-based study. <i>Journal of Headache and Pain</i> , 2014, 15, .	6.0	0
201	Lack of association between GRIA1 polymorphisms and haplotypes with migraine without aura or response to triptans. <i>Neurological Sciences</i> , 2014, 35, 421-427.	1.9	10
202	Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. <i>Cephalalgia</i> , 2014, 34, 594-604.	3.9	64
203	Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: A placebo controlled study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1140-1144.	2.2	51
204	Functional polymorphisms in <scp>COMT</scp> and <scp>SLC</scp>6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. <i>European Journal of Neurology</i> , 2014, 21, 989-995.	3.3	24
205	Access to care - an unmet need in headache management?. <i>Journal of Headache and Pain</i> , 2014, 15, 20.	6.0	18
206	The impact of headache in Europe: principal results of the Eurolight project. <i>Journal of Headache and Pain</i> , 2014, 15, 31.	6.0	267
207	Headache yesterday in Europe. <i>Journal of Headache and Pain</i> , 2014, 15, 33.	6.0	18
208	A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. <i>Cephalalgia</i> , 2014, 34, 645-655.	3.9	108
209	Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke. <i>Current Medicinal Chemistry</i> , 2014, 21, 2098-2117.	2.4	34
210	Serious games for screening pre-dementia conditions: from virtuality to reality? A pilot project. <i>Functional Neurology</i> , 2014, 29, 153-8.	1.3	26
211	Enhanced temporal pain processing in multiple system atrophy. <i>Neuroscience Letters</i> , 2013, 555, 203-208.	2.1	12
212	EUROLIGHT project: impact of primary headache disorders from a population-based study conducted in Pavia. <i>Journal of Headache and Pain</i> , 2013, 14, .	6.0	0
213	Disability caused by medication-overuse headache can be considerably reduced by detoxification. Results from multinational COMOESTAS study. <i>Journal of Headache and Pain</i> , 2013, 14, .	6.0	1
214	Effects of URB937 on an animal model of migraine pain. <i>Journal of Headache and Pain</i> , 2013, 14, .	6.0	1
215	The "œcare" protocol: the role of personality in a three-year follow-up study of medication overuse headache. <i>Journal of Headache and Pain</i> , 2013, 14, .	6.0	0
216	The "œcare" protocol: outcome of medication overuse headache in a three year follow-up study. <i>Journal of Headache and Pain</i> , 2013, 14, .	6.0	0

#	ARTICLE	IF	CITATIONS
217	Effect of Sex and Estrogens on Neuronal Activation in an Animal Model of Migraine. <i>Headache</i> , 2013, 53, 288-296.	3.9	39
218	An Opposite-Direction Modulation of the COMT Val158Met Polymorphism on the Clinical Response to Intrathecal Morphine and Triptans. <i>Journal of Pain</i> , 2013, 14, 1097-1106.	1.4	45
219	Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). <i>Contraception</i> , 2013, 88, 369-375.	1.5	52
220	Factors associated with a negative outcome of medication-overuse headache: A 3-year follow-up (the Tj ETQq0 0 0,rgBT /Overlock 10 Tt	3.9	33
221	In search of new targets for retinal neuroprotection: is there a role for autophagy?. <i>Current Opinion in Pharmacology</i> , 2013, 13, 72-77.	3.5	25
222	Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. <i>Journal of Headache and Pain</i> , 2013, 14, 10.	6.0	68
223	Diagnostic and therapeutic errors in trigeminal autonomic cephalalgias and hemicrania continua: a systematic review. <i>Journal of Headache and Pain</i> , 2013, 14, 14.	6.0	47
224	The Headache Under-Response to Treatment (HURT) Questionnaire: Assessment of utility in headache specialist care. <i>Cephalalgia</i> , 2013, 33, 245-255.	3.9	24
225	Illicit drug use in cluster headache patients and in the general population: A comparative cross-sectional survey. <i>Cephalalgia</i> , 2012, 32, 1031-1040.	3.9	35
226	Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2012, 169, 77-86.	2.8	65
227	Reduced-Intensity Modified Constraint-Induced Movement Therapy Versus Conventional Therapy for Upper Extremity Rehabilitation After Stroke. <i>Neurorehabilitation and Neural Repair</i> , 2012, 26, 1035-1045.	2.9	60
228	An electronic diary on a palm device for headache monitoring: a preliminary experience. <i>Journal of Headache and Pain</i> , 2012, 13, 537-541.	6.0	25
229	Death in pain: peripheral nerve injury and spinal neurodegenerative mechanisms. <i>Current Opinion in Pharmacology</i> , 2012, 12, 49-54.	3.5	5
230	Estimation of human trunk movements by wearable strain sensors and improvement of sensorâ€™s placement on intelligent biomedical clothes. <i>BioMedical Engineering OnLine</i> , 2012, 11, 95.	2.7	35
231	Transdermal Hormonal Therapy in Perimenstrual Migraine: Why, When and How?. <i>Current Pain and Headache Reports</i> , 2012, 16, 467-473.	2.9	17
232	Early rehabilitation after surgery improves functional outcome in inpatients with brain tumours. <i>Journal of Neuro-Oncology</i> , 2012, 107, 537-544.	2.9	112
233	Modulation of RAGE Isoforms Expression in the Brain and Plasma of Rats Exposed to Transient Focal Cerebral Ischemia. <i>Neurochemical Research</i> , 2012, 37, 1508-1516.	3.3	17
234	Italian guidelines for primary headaches: 2012 revised version. <i>Journal of Headache and Pain</i> , 2012, 13, 31-70.	6.0	129

#	ARTICLE	IF	CITATIONS
235	Association of haplotype combination of serotonin transporter gene polymorphisms with monthly headache days in MOH patients. <i>European Journal of Neurology</i> , 2012, 19, 69-75.	3.3	11
236	Acute Reduction of Anandamideâ€Hydrolase (FAAH) Activity is Coupled With a Reduction of Nociceptive Pathways Facilitation in Medicationâ€Overuse Headache Subjects After Withdrawal Treatment. <i>Headache</i> , 2012, 52, 1350-1361.	3.9	49
237	Sexual Function and Distress in Women Treated for Primary Headaches in a Tertiary University Center. <i>Journal of Sexual Medicine</i> , 2012, 9, 761-769.	0.6	26
238	The cost of headache disorders in Europe: the Eurolight project. <i>European Journal of Neurology</i> , 2012, 19, 703-711.	3.3	537
239	Pisa syndrome in Parkinson's disease: Clinical, electromyographic, and radiological characterization. <i>Movement Disorders</i> , 2012, 27, 227-235.	3.9	75
240	A basic diagnostic headache diary (BDHD) is well accepted and useful in the diagnosis of headache. A multicentre European and Latin American study. <i>Cephalalgia</i> , 2011, 31, 1549-1560.	3.9	56
241	The contribution of trigemino-cervical reflexes in distinguishing progressive supranuclear palsy from multiple system atrophy. <i>Clinical Neurophysiology</i> , 2011, 122, 1812-1815.	1.5	17
242	Differences in the Personality Profile of Medication-Overuse Headache Sufferers and Drug Addict Patients: A Comparative Study Using MMPI-2. <i>Headache</i> , 2011, 51, 1212-1227.	3.9	27
243	IkappaB-alpha expression following transient focal cerebral ischemia is modulated by nitric oxide. <i>Brain Research</i> , 2011, 1372, 145-151.	2.2	24
244	Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations. <i>Neurogenetics</i> , 2011, 12, 263-271.	1.4	16
245	Effects of anandamide in migraine: data from an animal model. <i>Journal of Headache and Pain</i> , 2011, 12, 177-183.	6.0	38
246	What do the patients with medication overuse headache expect from treatment and what are the preferred sources of information?. <i>Journal of Headache and Pain</i> , 2011, 12, 91-96.	6.0	28
247	Focus on the management of thunderclap headache: from nosography to treatment. <i>Journal of Headache and Pain</i> , 2011, 12, 251-258.	6.0	15
248	Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. <i>Journal of Headache and Pain</i> , 2011, 12, 427-433.	6.0	100
249	The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. <i>Journal of Headache and Pain</i> , 2011, 12, 541-549.	6.0	44
250	Facilitated temporal summation of pain at spinal level in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 442-448.	3.9	51
251	Oral nitric-oxide donor glyceryl-trinitrate induces sensitization in spinal cord pain processing in migraineurs: A double-blind, placebo-controlled, cross-over study. <i>European Journal of Pain</i> , 2011, 15, 482-490.	2.8	34
252	Neuroprotection by leptin in a rat model of permanent cerebral ischemia: effects on STAT3 phosphorylation in discrete cells of the brain. <i>Cell Death and Disease</i> , 2011, 2, e238-e238.	6.3	45

#	ARTICLE	IF	CITATIONS
253	Temporal profile of vascular changes induced by systemic nitroglycerin in the meningeal and cortical districts. <i>Cephalalgia</i> , 2011, 31, 190-198.	3.9	36
254	The Use of Diaries in the Management of Headache. , 2011, , 197-209.		3
255	Focus on therapy of primary stabbing headache. <i>Journal of Headache and Pain</i> , 2010, 11, 157-160.	6.0	14
256	Focus on therapy: hemicrania continua and new daily persistent headache. <i>Journal of Headache and Pain</i> , 2010, 11, 259-265.	6.0	21
257	A prospective multicentre study to evaluate the consistency of the IHS diagnostic criteria, the usefulness of brain MRI for the diagnosis, follow-up and treatment management, and the outcome after high dosage 6-methylprednisolone therapy, in subjects with Tolosa-Hunt syndrome. <i>Journal of Headache and Pain</i> , 2010, 11, 285-285.	6.0	4
258	Focus on therapy of hypnic headache. <i>Journal of Headache and Pain</i> , 2010, 11, 349-354.	6.0	20
259	Focus on therapy of the Chapter IV headaches provoked by exertional factors: primary cough headache, primary exertional headache and primary headache associated with sexual activity. <i>Journal of Headache and Pain</i> , 2010, 11, 525-530.	6.0	26
260	The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients. <i>European Journal of Pharmacology</i> , 2010, 641, 82-87.	3.5	35
261	Identification of distinct cellular pools of interleukin-1 β during the evolution of the neuroinflammatory response induced by transient middle cerebral artery occlusion in the brain of rat. <i>Brain Research</i> , 2010, 1313, 259-269.	2.2	32
262	Four-week trunk-specific rehabilitation treatment improves lateral trunk flexion in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 325-331.	3.9	62
263	Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat. <i>Cephalalgia</i> , 2010, 30, 296-302.	3.9	52
264	Role of 2 Common Variants of 5HT2A Gene in Medication Overuse Headache. <i>Headache</i> , 2010, 50, 1587-1596.	3.9	16
265	An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 54-60.	1.9	81
266	Development and validation of the EUROLIGHT questionnaire to evaluate the burden of primary headache disorders in Europe. <i>Cephalalgia</i> , 2010, 30, 1082-1100.	3.9	38
267	Experimental models of migraine. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2010, 97, 109-123.	1.8	23
268	The endocannabinoid system and migraine. <i>Experimental Neurology</i> , 2010, 224, 85-91.	4.1	58
269	Chapter 28 Identification of Novel Pharmacological Targets to Minimize Excitotoxic Retinal Damage. <i>International Review of Neurobiology</i> , 2009, 85, 407-423.	2.0	28
270	Implementation and evaluation of existing guidelines on the use of neurophysiological tests in non-acute migraine patients: a questionnaire survey of neurologists and primary care physicians. <i>European Journal of Neurology</i> , 2009, 16, 937-942.	3.3	5

#	ARTICLE	IF	CITATIONS
271	Medication Overuse Headache and Applicability of the ICHD-II Diagnostic Criteria: 1-Year Follow-Up Study (CARE I Protocol). Cephalalgia, 2009, 29, 233-243.	3.9	47
272	Eletriptan. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1587-1598.	3.3	10
273	The role of rehabilitation in deep brain stimulation of the subthalamic nucleus for Parkinson's disease: A pilot study. Parkinsonism and Related Disorders, 2009, 15, 675-681.	2.2	25
274	Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. Neuroscience Letters, 2009, 467, 203-207.	2.1	75
275	Effects of systemic administration of the essential oil of bergamot (BEO) on gross behaviour and EEG power spectra recorded from the rat hippocampus and cerebral cortex. Functional Neurology, 2009, 24, 107-12.	1.3	25
276	Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurological Sciences, 2008, 29, 360-363.	1.9	46
277	Lack of trigemino-cervical reflexes in progressive supranuclear palsy. Movement Disorders, 2008, 23, 1475-1479.	3.9	14
278	Reduced Habituation of Trigeminal Reflexes in Patients with Episodic Cluster Headache During Cluster Period. Cephalalgia, 2008, 28, 950-959.	3.9	36
279	The Usefulness and Applicability of a Basic Headache Diary Before First Consultation: Results of a Pilot Study Conducted In Two Centres. Cephalalgia, 2008, 28, 1023-1030.	3.9	32
280	Modulation of pro-survival and death-associated pathways under retinal ischemia/reperfusion: effects of NMDA receptor blockade. Journal of Neurochemistry, 2008, 107, 1347-1357.	3.9	47
281	Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia. Brain Research, 2008, 1238, 215-223.	2.2	28
282	5-hydroxytryptamine _{1B} receptor and triptan response in migraine, lack of association with common polymorphisms. European Journal of Pharmacology, 2008, 580, 43-47.	3.5	19
283	Use of complementary and alternative medicine by patients with cluster headache: Results of a multi-centre headache clinic survey. Complementary Therapies in Medicine, 2008, 16, 220-227.	2.7	20
284	Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia, 2008, 28, 114-26.	3.9	58
285	Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia: a study in the rat. , 2008, , 219-222.		0
286	ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology, 2007, 68, 1557-1562.	1.1	312
287	A Role for Brain Cyclooxygenase-2 and Prostaglandin-2 in Migraine: Effects of Nitroglycerin. International Review of Neurobiology, 2007, 82, 373-382.	2.0	36
288	Homocysteine and Parkinson's disease: A dangerous liaison?. Journal of the Neurological Sciences, 2007, 257, 31-37.	0.6	49

#	ARTICLE	IF	CITATIONS
289	Neuroprotective Effect of Nitroglycerin in a Rodent Model of Ischemic Stroke: Evaluation of Bcl-2 Expression. <i>International Review of Neurobiology</i> , 2007, 82, 423-435.	2.0	21
290	Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17 β -estradiol. <i>FEBS Journal</i> , 2007, 274, 4464-4775.	4.7	51
291	Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. <i>Brain Research</i> , 2007, 1176, 53-61.	2.2	34
292	Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes. <i>Neurology</i> , 2007, 68, 583-589.	1.1	85
293	Peripheral Levels of BDNF and NGF in Primary Headaches. <i>Cephalalgia</i> , 2006, 26, 136-142.	3.9	63
294	Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat. <i>Experimental Neurology</i> , 2006, 200, 240-244.	4.1	1
295	Cardiovascular dysautonomia as a cause of falls in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 195-204.	2.2	21
296	Uncommon primary headaches. <i>Current Opinion in Neurology</i> , 2006, 19, 299-304.	3.6	15
297	Animal models of migraine: looking at the component parts of a complex disorder. <i>European Journal of Neuroscience</i> , 2006, 24, 1517-1534.	2.6	110
298	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , 2006, 14, 322-331.	2.8	152
299	Prostaglandins, glutamate and nitric oxide synthase mediate nitroglycerin-induced hyperalgesia in the formalin test. <i>European Journal of Pharmacology</i> , 2006, 534, 103-107.	3.5	40
300	Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat. <i>Brain Research</i> , 2006, 1101, 145-150.	2.2	7
301	Botulinum toxin and neuromotor rehabilitation: An integrated approach to idiopathic cervical dystonia. <i>Movement Disorders</i> , 2006, 21, 2240-2243.	3.9	103
302	Secondary cervical dystonia in iatrogenic hypoparathyroidism associated with extensive brain calcifications. <i>Functional Neurology</i> , 2006, 21, 165-6.	1.3	8
303	Parthenolide is the Component of Tanacetum Parthenium that Inhibits Nitroglycerin-Induced Fos Activation: Studies in an Animal Model of Migraine. <i>Cephalalgia</i> , 2005, 25, 612-621.	3.9	76
304	Comparative analysis of the neuronal activation and cardiovascular effects of nitroglycerin, sodium nitroprusside and l-arginine. <i>Brain Research</i> , 2005, 1051, 17-24.	2.2	20
305	Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 1439-1448.	3.9	219
306	Pharmacological properties of nimesulide. , 2005, , 133-244.		4

#	ARTICLE	IF	CITATIONS
307	Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes. <i>Neurology</i> , 2005, 65, 87-95.	1.1	323
308	Effects of acute and chronic restraint stress on nitroglycerin-induced hyperalgesia in rats. <i>Neuroscience Letters</i> , 2005, 383, 7-11.	2.1	63
309	Activation of the Transcription Factor NF- κ B in the Nucleus Trigeminalis Caudalis in an Animal Model of Migraine. <i>NeuroToxicology</i> , 2005, 26, 795-800.	3.0	49
310	Reliability of the Nitroglycerin Provocative Test in the Diagnosis of Neurovascular Headaches. <i>Cephalalgia</i> , 2004, 24, 110-119.	3.9	127
311	Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. <i>Journal of Neural Transmission</i> , 2004, 111, 1017-30.	2.8	58
312	Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. <i>Journal of Chemical Neuroanatomy</i> , 2004, 27, 23-32.	2.1	32
313	Long-Term Evaluation of the Effect of Quetiapine on Hallucinations, Delusions and Motor Function in Advanced Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 33-37.	0.7	27
314	A questionnaire on sleep and mental disorders in Parkinson's disease (QSMDDP): development and application of a new screening tool. <i>Functional Neurology</i> , 2004, 19, 83-99.	1.3	11
315	Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease. <i>Neurological Sciences</i> , 2003, 24, 157-158.	1.9	16
316	Nitroglycerin induces hyperalgesia in rats—a time-course study. <i>European Journal of Pharmacology</i> , 2003, 464, 159-162.	3.5	98
317	Selective stimulation of striatal dopamine receptors of the D1- or D2-class causes opposite changes of fos expression in the rat cerebral cortex. <i>European Journal of Neuroscience</i> , 2003, 17, 763-770.	2.6	23
318	Peripheral and Central Activation of Trigeminal Pain Pathways in Migraine: Data From Experimental Animal Models. <i>Cephalalgia</i> , 2003, 23, 1-4.	3.9	36
319	Central Components of the Analgesic/Antihyperalgesic Effect of Nimesulide. <i>Drugs</i> , 2003, 63, 9-22.	10.9	31
320	Electrophysiological evidence for trigeminal neuron sensitization in patients with migraine. <i>Neuroscience Letters</i> , 2002, 317, 135-138.	2.1	77
321	Effects of nimesulide on nitric oxide-induced hyperalgesia in humans—a neurophysiological study. <i>European Journal of Pharmacology</i> , 2002, 450, 259-262.	3.5	29
322	Effects of the intrastratial administration of selective dopaminergic agonists on Fos expression in the rat brain. <i>Neurological Sciences</i> , 2002, 23, s57-s58.	1.9	2
323	Nitroglycerin-Induced Activation of Monoaminergic Transmission in the Rat. <i>Cephalalgia</i> , 2002, 22, 226-232.	3.9	29
324	Changes in Nociceptive Flexion Reflex Threshold Across the Menstrual Cycle in Healthy Women. <i>Psychosomatic Medicine</i> , 2002, 64, 621-626.	2.0	60

#	ARTICLE	IF	CITATIONS
325	Intrastriatal injection of D1 or D2 dopamine agonists affects glucose utilization in both the direct and indirect pathways of the rat basal ganglia. <i>Neuroscience Letters</i> , 2001, 309, 161-164.	2.1	16
326	Nitric oxide-induced neuronal activation in the central nervous system as an animal model of migraine: mechanisms and mediators. <i>Functional Neurology</i> , 2001, 16, 69-76.	1.3	18
327	Functional changes of the basal ganglia circuitry in Parkinson's disease. <i>Progress in Neurobiology</i> , 2000, 62, 63-88.	5.7	477
328	Effect of nitric oxide donors on the central nervous system–nitroglycerin studies in the rat. <i>Functional Neurology</i> , 2000, 15 Suppl 3, 19-27.	1.3	6
329	Reciprocal circuits involved in nitroglycerin-induced neuronal activation of autonomic regions and pain pathways: a double immunolabeling and tract-tracing study. <i>Brain Research</i> , 1999, 842, 294-310.	2.2	12
330	The effects on the central nervous system of nitroglycerin—putative mechanisms and mediators. <i>Progress in Neurobiology</i> , 1999, 57, 607-624.	5.7	81
331	Experimental models for the study of cluster headache. <i>Italian Journal of Neurological Sciences</i> , 1999, 20, S21-S24.	0.1	2
332	Combined evaluation of pupillary and cardiovascular responses to cold pressor test in cluster headache patients. <i>Cephalalgia</i> , 1998, 18, 668-674.	3.9	11
333	Neurochemical mechanisms of nitroglycerin-induced neuronal activation in rat brain: A pharmacological investigation. <i>Neuropharmacology</i> , 1997, 36, 1417-1424.	4.1	45
334	Systemic nitroglycerin activates peptidergic and catecholaminergic pathways in rat brain. <i>Peptides</i> , 1996, 17, 443-449.	2.4	13
335	NF- κ B transcription factor subunits in rat brain: Colocalization of p65 and κ -MSH. <i>Peptides</i> , 1996, 17, 655-664.	2.4	12
336	Sleep-apnoea and autonomic dysfunction: a cardiopressor and pupillometric study. <i>Acta Neurologica Scandinavica</i> , 1995, 91, 382-388.	2.1	13
337	Increased Cerebral Blood Flow Velocity Induced by Cold Pressor Test in Migraine: A Possible Basis for Pathogenesis?. <i>Cephalalgia</i> , 1995, 15, 494-498.	3.9	16
338	Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. <i>Brain Research</i> , 1995, 682, 167-181.	2.2	224
339	NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration. <i>Brain Research</i> , 1995, 695, 37-44.	2.2	63
340	Pupillary and cardiovascular responses to the cold-pressor test. <i>Journal of the Autonomic Nervous System</i> , 1995, 55, 45-49.	1.9	48
341	Bilateral Asymmetry of Cerebral Blood Velocity in Cluster Headache. <i>Cephalalgia</i> , 1994, 14, 346-351.	3.9	8
342	Intracerebral vascular changes induced by cold pressor test: A model of sympathetic activation. <i>Neurological Research</i> , 1994, 16, 163-167.	1.3	48

#	ARTICLE	IF	CITATIONS
343	The Trigemino-Pupillary Response in Cluster Headache. Cephalalgia, 1993, 13, 338-342.	3.9	9
344	Effectiveness of a Piroxicam Fast Dissolving Formulation Sublingually Administered in the Symptomatic Treatment of Migraine Without Aura. Headache, 1993, 33, 296-300.	3.9	16
345	Imbalance of heart rate regulation in cluster headache as based on continuous 24-h recordings. Clinical Autonomic Research, 1993, 3, 291-298.	2.5	24
346	The trigemino-pupillary reflex: a model of sensory-vegetative integration. Journal of the Autonomic Nervous System, 1992, 41, 179-185.	1.9	10
347	The Role of PO ₂ /PCO ₂ in Cluster Headache Pathogenesis: Perspectives of the Oxygen/Ozone Therapy. Cephalalgia, 1991, 11, 272-273.	3.9	1
348	Evidence for the Impairment of Sensory/Nociceptive Integrative Processes in Cluster Headache. The Trigeminal Reflex. Cephalalgia, 1991, 11, 242-243.	3.9	2
349	Disordered pupil reactivity in Parkinson's disease. Clinical Autonomic Research, 1991, 1, 55-58.	2.5	76
350	Cluster Headache Course Over Ten Years in 189 Patients. Cephalalgia, 1991, 11, 169-174.	3.9	154
351	Effectiveness of Salmon Calcitonin Nasal Spray Preparation in the Treatment of "Chronic" Headache Form. Cephalalgia, 1989, 9, 400-401.	3.9	1
352	Pupil Responsiveness in Cluster Headache: A Dynamic TV Pupillometric Evaluation. Cephalalgia, 1988, 8, 193-201.	3.9	25
353	Electronic pupillometry for investigating pupil reactivity to different exteroceptive stimuli: applications and limits. Functional Neurology, 1987, 2, 529-38.	1.3	3